Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OBADIAS MARQUEZ

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174597546
CMS profile
234867
Location
OOLTEWAH, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,236.30

226 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,221.89 223
Education $14.41 3

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OBADIAS MARQUEZ

NPI 1174597546 · CMS profile ID 234867

Allopathic & Osteopathic Physicians / Internal Medicine

OOLTEWAH, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174597546?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OBADIAS MARQUEZ, NPI 1174597546, CMS profile ID 234867. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174597546?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). OBADIAS MARQUEZ, NPI 1174597546, CMS profile ID 234867. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174597546?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
OBADIAS MARQUEZ, NPI 1174597546, CMS profile ID 234867, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174597546?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

226 matching records · $4,236.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 226 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 226.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $14.7004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820068722 CMS
Janssen Pharmaceuticals, Inc $11.3404/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956215 CMS
Novo Nordisk Inc $14.8004/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811196837 CMS
Biohaven Pharmaceuticals, Inc. $14.1704/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559471 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.2904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763669518 CMS
AbbVie Inc. $17.7904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509755 CMS
AbbVie Inc. $6.6404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509749 CMS
Kowa Pharmaceuticals America, Inc. $13.3804/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805526503 CMS
Novo Nordisk Inc $18.1104/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811341933 CMS
Ironwood Pharmaceuticals, Inc $19.7504/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855101265 CMS
Janssen Pharmaceuticals, Inc $25.0204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956187 CMS
Janssen Pharmaceuticals, Inc $1.9204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956189 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.2104/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850349699 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1804/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850401523 CMS
Esperion Therapeutics, Inc. $23.5704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838349151 CMS
Lilly USA, LLC $12.3004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818685005 CMS
Biohaven Pharmaceuticals, Inc. $14.4604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559469 CMS
Janssen Pharmaceuticals, Inc $21.3104/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956181 CMS
ARBOR PHARMACEUTICALS, INC. $14.1604/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830950603 CMS
Amarin Pharma Inc. $20.4104/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815280567 CMS
Janssen Pharmaceuticals, Inc $33.9904/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956213 CMS
Janssen Pharmaceuticals, Inc $20.8204/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956211 CMS
Novo Nordisk Inc $18.6804/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810674479 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.6103/31/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850269271 CMS
Amgen Inc. $14.5803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825667191 CMS
Novo Nordisk Inc $20.5103/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811196831 CMS
Biohaven Pharmaceuticals, Inc. $14.1703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559467 CMS
PFIZER INC. $15.7603/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832572211 CMS
Janssen Pharmaceuticals, Inc $15.1503/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956203 CMS
Biohaven Pharmaceuticals, Inc. $10.9403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559465 CMS
Lilly USA, LLC $10.4603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818721477 CMS
AbbVie Inc. $29.8303/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509745 CMS
Novo Nordisk Inc $14.8303/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811718577 CMS
Lilly USA, LLC $1.0003/18/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818717309 CMS
AbbVie Inc. $42.6503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509739 CMS
AbbVie Inc. $12.1703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509733 CMS
Biohaven Pharmaceuticals, Inc. $16.4403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559463 CMS
Novo Nordisk Inc $18.6403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811196827 CMS
AbbVie Inc. $10.7403/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509727 CMS
Abbott Laboratories $18.8103/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818435125 CMS
Lilly USA, LLC $12.1703/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818673415 CMS
AbbVie Inc. $16.3403/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509721 CMS
Novo Nordisk Inc $18.8603/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000729 CMS
Xeris Pharmaceuticals, Inc. $12.7803/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837434039 CMS
AbbVie Inc. $4.3803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795509715 CMS
Lilly USA, LLC $23.3403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818685681 CMS
Lilly USA, LLC $2.5403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818711921 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.5303/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850196651 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.3903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850367561 CMS
Novo Nordisk Inc $16.4902/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811718573 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,517.57 150
PY2020 $2,639.83 165
PY2021 $4,236.30 226
PY2022 $3,641.51 211
PY2023 $3,507.77 166
PY2024 $3,257.79 138
PY2025 $3,382.28 123

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $211.50 2
PY2025 Principal investigator $834,517.30 49
PY2024 Recipient $4,998.20 3
PY2024 Principal investigator $976,411.22 50
PY2023 Principal investigator $925,811.97 25
PY2022 Principal investigator $22,570.83 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,057.40 11/25/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085314
Principal investigator 1 Genentech, Inc. $3,024.00 11/21/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211685478
Principal investigator 1 Genentech, Inc. $4,104.00 11/21/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211685480
Principal investigator 1 Eli Lilly and Company $6,957.00 11/18/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCI
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187893462
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $40.50 10/07/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085312
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $868.05 10/07/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085316
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $41.85 10/07/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085318
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $41.85 10/07/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085320
Principal investigator 1 Genentech, Inc. $1,008.00 10/02/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211685476
Principal investigator 1 Eli Lilly and Company $282.51 10/01/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187892336
Recipient Eli Lilly and Company $24.50 09/15/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187871759
Principal investigator 1 Genentech, Inc. $3,096.00 09/02/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621904
Principal investigator 1 Genentech, Inc. $2,016.00 08/12/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621900
Principal investigator 1 Verona Pharma, Inc. $10,000.00 08/08/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891331
Principal investigator 1 Verona Pharma, Inc. $1,800.00 08/08/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891333
Recipient GlaxoSmithKline, LLC. $187.00 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192138211
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $40.50 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085294
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $450.00 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085296
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $868.05 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085298
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $41.85 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085300
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $41.85 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085302
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $45.90 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085304
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $600.00 06/21/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085308
Principal investigator 1 Genentech, Inc. $3,024.00 06/17/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621886
Principal investigator 1 Genentech, Inc. $3,096.00 06/17/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621896
Principal investigator 1 Genentech, Inc. $10,000.00 06/10/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621878
Principal investigator 1 Genentech, Inc. $1,000.00 06/10/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621882
Principal investigator 1 Genentech, Inc. $5,688.00 06/10/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211621891
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,608.45 05/30/2025 Non-covered Recipient Entity
WR-CLINSEARCH LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185544265
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $868.05 05/17/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085306
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,077.10 04/23/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185544269
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,766.25 04/02/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185544271
Principal investigator 1 Eli Lilly and Company $187.50 03/25/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187872289
Principal investigator 1 Genentech, Inc. $3,154.00 03/18/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211621867
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,611.25 03/13/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085286
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,400.00 03/13/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085288
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $978.00 03/13/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085290
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $8,500.00 03/13/2025 Non-covered Recipient Entity
WR Clinsearch LLC
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240085292
Principal investigator 1 Eli Lilly and Company $2,700.00 03/03/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187893500
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,852.00 02/26/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185544273
Principal investigator 1 Genentech, Inc. $8,599.00 02/25/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211621870
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,858.40 02/21/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185544263
Principal investigator 1 Eli Lilly and Company $341.45 02/17/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187892334
Principal investigator 1 Eli Lilly and Company $173.28 02/10/2025 Non-covered Recipient Entity
CLINSEARCH LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187879773
Principal investigator 1 Eli Lilly and Company $214,312.00 02/04/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187892524
Principal investigator 1 Eli Lilly and Company $1,896.71 01/30/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187893502
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,871.55 01/29/2025 Non-covered Recipient Entity
WR-MSRA LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185544267
Principal investigator 1 Eli Lilly and Company $51,391.00 01/21/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891928
Principal investigator 1 Eli Lilly and Company $142,696.00 01/07/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187891930
Principal investigator 1 Eli Lilly and Company $216,908.00 01/07/2025 Non-covered Recipient Entity
WR CLINSEARCH LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187893916
Principal investigator 1 Genentech, Inc. $6,534.00 01/02/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211621874